Statera Biopharma, Inc. · OTC:STAB
Statera Biopharma — Cleveland Biolabs — Virtual Conference, January 11-14, 2021
20 slides from Statera Biopharma's conference presentation, Jan 8, 2021
Slide 1: Cytocom, Inc. Virtual Conference January 11-14, 2021
Inc. cylocem ty ots Developing a new generation of therapeutics delivering immune homeostasis across a broad range of indications in cancer and autoimmune diseases , ey) January 11-14, 2021 President & CEO VIRTUAL CONFERENCE Cytocom, Inc.
Slide 2: Legal Disclaimer
Legal Disclaimer Management believes the material contained within this presentationis an accurate description of corporate, scientific and market fats; some dislosuteincludestorward- lockingstatements that may or may ntcome true. ASsuch, the viewer acknowledges that this presentations nt tobe used
Slide 3: Cytocom, Inc. - A Multi-faceted Growth Opportunity
Cytocom, Inc. - A Multi-faceted Growth Opportunity Cytocom Foundation Cleveland Biolabs (Nasdaq: CBLI) + Clinical-stagebiopharma company + Merger agreement announced Oct. 20,2020 + Novel immune modulating therapies + Cytocom will assumeleadership of NASDAQ + Strategy focused onimmunehomeostasis comp
Slide 4: Leadership
e Leadership Peter Aronstam ~ CFO LDiector Peter has more than 30 years of expetiencein accounting finance, banking international ade, and aw. Mr, Aronstamhas a6vised and/or served as CFO in both publicly held and privately ike K. Handley - President, CEO & Diector Successful pharmaceutical executiv
Slide 5: The Problem / The Solution
The Problem: ‘Advanced Immunotherapy Multi- LMS, receptor System The Solution: @ + Single-target drugs can be inadequate at achieving therapeutic effect in complex pathologies + Multifactorial processes involve multiple signaling pathways & dysregulation + Many diseases require modulation of multipl
Slide 6: Moving Beyond the Classic Paradigm of One Target One Drug
Moving Beyond the Classic Paradigm of One Target One Drug AIMS: develop multi-target therapies delivering immune homeostasis and a reduction in off-target mechanisms Ory tab Computational Methods & Analysis Tegel vay, ==> Novel Drug ei waub Discovery aa Methods& Analysis Als. Drig-Target Network Pro
Slide 7: AIMS Platform: Therapies Delivering Immune Homeostasis
AIMS™ Platform: Therapies Delivering Immune Homeostasis Advanced Immunotherapy Multi-receptor System Th2 Thi Thi Tha Autoimmune Cancer Thi Th2 AIMS” Targeted Modulation Leading to Homeostasis ‘AIMS™ 200 | AIMS™ 400 er cytocem a
Slide 8: Cytocom, Inc. Pipeline
Cytocom, Inc. Pipeline Programs | | | eee Bicone cytocem E
Slide 9: Crohn's Opportunity - CYTO-201
Crohn’s Opportunity - CYTO-201 Position: Oral therapy with long-term safety at low doses for early intervention to maintain prolonged remission through mucosal healing leading to improved outcomes Phase 2 study supporting proof of concept and safety Phase 2 study with remission in 67% and 43% true m
Slide 10: Pancreatic Cancer Opportunity - CYTO-401
Pancreatic Cancer Opportunity - CYTO-401 Position: IV therapy with long-term safety & potential to improve the clinical benefit and prolong survival by stabilizing disease or slowing progression + Phase2 study supporting proof of concept and safety + IND Number 50,987 Phase 2b/3 Ready Trial expected
Slide 11: Primary Market Opportunities
Primary Market Opportunities | Fibromyatgia US=5125,764 The oat mare fr ttvemiga nrapis TPM us rcgsausstas it ac Sa ‘orted to ro on inn 250 to apyonnaey aes Intvensa US= 45,000,000 Theplobalus market wasvaledats i prjecteatore the pobulnlens retment indy i proc to Pancreatic Cancer Us=49424 covio-s
Slide 12: Cleveland BioLabs: Merger Opportunity
P cleveland BioLabs Merger Opportunity
Slide 13: Cleveland Biolabs - Current State
Cleveland Biolabs (NASDAQ: CBLI) - Current State Public biotech with synergistic immune homeostasis assets and late-stage acute radiation syndrome (“ARS”) therapy * Seeking the ability to rapidly move forward with ARS authorization (pre-EUA) * Requires necessary infrastructure to complete valuable n
Slide 14: CBLI Opportunity Overview
CBLI Opportunity Overview Assets: Synergies: * 25+ patents |* Both companiesare focused on * Clinical stage TLR5 agonist immune homeostasis Partner: + Forefront of multi-receptor polypharmacology platforms * RTL1and ENL1 inhibitors . . . * T-Cell stimulation * Adaptive T-cell therapy . . + Vaccine a
Slide 15: CBLI + Cytocom Post Merger Potential
CBLI + Cytocom Post Merger Potential + CBLI merger closing expected Q2 2021 + ImQuest acquisition finalized expected Q1 2021 CBLI+CYTOCOM ImQuest Life Sciences, LLC Genome Protection, Inc. (50%) | (Wholly Owned Subsidiary) | (Exclusive license to GP532 (entolimod variant) for genome damage J and agi
Slide 16: ImQuest BioSciences
ImQuest BioSciences ImQuest Biosciences Provides expert services to evaluate the potential of novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases. These preclinical research services are pat of the ImQuestSUCCESS Platform Virosens Mic
Slide 17: Anticipated Milestones
Anticipated Milestone: Q2 2021 Qt 2021 ~* Close CBLI merger : + Pancreatic ipelin + C¥TO-101 500k este cancer Phase 3 ‘manufacturing atts AIMS Platform study initiation = COVID-19 Phase 2 Cleveland Biolabs study initiation = FDA meeting to finalize Phase 3 program SEEN cytocem jv
Slide 18: Intellectual Property
Intellectual Property * Combined company represents 30+ patents surrounding multi-receptor combinations of immune modulatory agents * Cytocom intends to file for additional patent protections surrounding expanded AIMS platforms strengthening our position in immune homeostasis cytocem E
Slide 19: Cytocom Inc. History Snapshot
cytoc © December2020 Inc, History Snapshot * Spin off from Immune Therapeutics in * Merger Signing with Cleveland late 2014 BioLabs (NASDAQ: CBLI) + 15 patents * Research coalition witha * Approach to drug development uses top immunology research organization immune modulation as a cornerstone * Def
Slide 20: Michael K. Handley: CEO
Michael K. Handley: CEO +1-888-629-4155 y info@cytocom.com www.cytocom.com
Cleveland Biolabs — Virtual Conference, January 11-14, 2021 on 6ix